SAR-441121(SAR-441121) - 在研适应症：疟疾_专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [4]

靶点-

作用机制-

治疗领域

感染

在研适应症

疟疾

非在研适应症-

原研机构

Sanofi

在研机构

Sanofi

MMV Medicines for Malaria Venture

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 SAR-441121 相关的临床试验

NCT05205941 / Completed临床1期IIT

A Phase 1b Study to Assess the Safety, Tolerability and Antimalarial Activity of MMV533 Against Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers

A Phase 1b study to assess the safety, tolerability and antimalarial activity of MMV533 against Plasmodium falciparum 3D7 blood stage infection in healthy volunteers

开始日期2022-03-30

申办/合作机构

MMV Medicines for Malaria Venture

[+2]

NCT04323306 / Completed临床1期IIT

A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single Doses of MMV533, Including a Pilot Food Evaluation in Healthy Participants.

Phase 1, single -centre study in 2 parts. The study designs for each part are well established for first-in-human studies and are appropriate to assess safety, tolerability and preliminary pharmacokinetics.

开始日期2020-08-12

申办/合作机构

MMV Medicines for Malaria Venture

[+2]

ACTRN12618001783213 / Recruiting临床1期

A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Single Ascending Doses of SAR441121 Including a Pilot Food Evaluation (TDU15302) and its Antimalarial Activity against Plasmodium falciparum Blood Stage Infection (PDY15303) in Healthy Male Subjects.

开始日期2018-10-29

申办/合作机构-

100 项与 SAR-441121 相关的临床结果

登录后查看更多信息

100 项与 SAR-441121 相关的转化医学

登录后查看更多信息

100 项与 SAR-441121 相关的专利（医药）

登录后查看更多信息

3

项与 SAR-441121 相关的文献（医药）

2021-07-21·Science Translational Medicine1区 · 医学

The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance

1区 · 医学

Article

作者: Singh, Shivendra ; Mok, Sachel ; Cabanis, Marie-José ; Tuffal, Gilles ; Sallé, Laurent ; Cooper, Roland A. ; Fraisse, Laurent ; Wirjanata, Grennady ; Bashyam, Sridevi ; Boulenc, Xavier ; Joseph, Jayan ; Vermat, Thierry ; Fidock, David A. ; Merino, Rita ; Augereau, Jean Michel ; Pascal, Cécile ; Guillon, Jean-Michel ; Baud, Delphine ; Sanz, Laura M. ; Menegotto, Jérôme ; Wittlin, Sergio ; Jiménez-Díaz, María Belén ; Tumwebaze, Patrick ; Cherkaoui-Rbati, Mohammed H. ; Rosenthal, Philip J. ; Courtemanche, Gilles ; Rubiano, Kelly ; Pasaje, Charisse Flerida A. ; Gnädig, Nina F. ; Bessila, Nadir ; Rouillier, Mélanie ; Desert, Paul ; Angulo-Barturen, Iñigo ; Gamo, Francisco Javier ; Niles, Jacquin C. ; Noviyanti, Rintis ; Bath, Jade ; Bozec, Tanguy ; Escudié, Fanny ; Blasco, Benjamin ; Marfurt, Jutta ; Doubovetzky, Michel ; Yeo, Tomas ; Bebrevska, Lidiya ; Klieber, Sylvie ; Price, Ric N. ; Pellet, Alain ; Campbell, Simon ; Uhlemann, Anne-Catrin ; Gobeau, Nathalie ; Giraud, Elie ; Murithi, James M. ; Leroy, Didier ; Louit, Guillaume ; Nicolas, Marie Françoise

We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.

Chemical Science

A focus on sustainable method development for greener synthesis

Article

作者: Glorius, Frank ; Tyler, Jasper L ; Katzenburg, Felix

Kavthe et al. (Chem. Sci., 2023, https://doi-org.libproxy1.nus.edu.sg/10.1039/D3SC01699D) have demonstrated how employing more sustainable methodology can vastly reduce the environmental impact associated with the synthesis of the antimalarial drug candidate MMV688533.

Chemical Science

A sustainable, efficient, and potentially cost-effective approach to the antimalarial drug candidate MMV688533

Article

作者: Iyer, Karthik S. ; Caravez, Juan C. ; Lipshutz, Bruce H. ; Kavthe, Rahul D.

A 6-step synthesis of the antimalarial drug candidate MMV688533 is reported.

100 项与 SAR-441121 相关的药物交易

登录后查看更多信息